Roche announced today a deal with Santaris to make RNA based drugs. The Santaris platform, known as locked nucleic acid (LNA), can be used against a variety of targets in several diseases. Roche will pay $10 M upfront plus up to $138 M in milestones. It will further fund discovery and research, and will pay royalties upon commercialization of any products. A Roche spokesman said that the company believes the LNA platform will allow it to discover novel drugs against a range of targets of high clinical relevance that cannot be targeted by other drug platforms today. See PharmaTimes.
Posted by Bruce Lehr Jan 10th 2013.